Aslan Pharmaceuticals
- Country
- 🇸🇬Singapore
- Ownership
- -
- Employees
- 35
- Market Cap
- $1.6M
- Introduction
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for...
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT03093870
- Locations
- 🇺🇸
Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇯🇵There are 7 sites in different cities in Japan, Chiba, Japan
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03082053
- Locations
- 🇯🇵
ASLAN Selected sites, Tokyo, Japan
Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
- Conditions
- Interventions
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 204
- Registration Number
- NCT02992340
Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02648425
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
🇭🇰Queen Mary Hospital, Hong Kong, Hong Kong
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2018-05-29
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02609958
A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT02342652
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT02338245
- Locations
- 🇵🇭
Philippines, Dasmarinas, Philippines
🇸🇬Singapore, Singapore, Singapore
🇦🇺Australia, Western Australia, Australia
Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT01992367
A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
- First Posted Date
- 2012-11-04
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 39
- Registration Number
- NCT01721148
A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2
- Conditions
- Interventions
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01614522
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of